>> regeneron, the -- the minn monoclonal antibodies from regeneron are a very effective therapy for peopleho are sick early in their illness, who have not yet developed their own effective antibody response. so, you know, it tells me that they worried about the survival of the president. but there is another revelation in that book which describes the white house doctors, at some point, considering putting him on oxygen in the white house and hoping for the best, which is shockingly reckless. you know, the president of the united states was 74 years old. obviously, clearly obese. obesity is a risk factor for morality, as is age over 70. so he had multiple risk factors for dying of this virus. then they demonstrated that his ox oxygenation level of 86%, which is dangerously low, those should have triggered an immediate admission to walter reed, without hesitation. the president was in danger of dying. >> all of the lies here, how infuriating is that, knowing that you had white house officials, skpand even the doct involved in all of this, pushing back on the real picture that reporters were

. >> we have breaking news from regeneron, meg tirrell joins with us more hi, meg. >> hey, joe. are data showing that their monoclonal antibody cocktails lose potency against the omicron data there are actual lab data. they confirm this cocktail had potency against the dell that which is the dominant variant circulating. omicron is growing quickly they say they have next generation drugs active. we are now seeing the lab data coming out here and it's fairly concerning if we don't yet have the anti-viral doctor ug from pfizer and merck, which do stand up against the variant as you wait to get them updated as we need them to be against omicron, guys >> yeah. that probably, watching the stop, watching the overall averages, it's an anti-body monoclonal we know about vaccine generated anti-bodies to omicron are far less effective than to the other variants why wouldn't the monoclonal be expected to be less effective. is this surprising in anyway, meg, thing eanything that we miv assumed? >> this was expected a. paper came out, a pre-print, not a peer preview from dr. david ho at colo

cnbc's meg tirrell covers health and science for us you heard from the regeneron ceo today? >> yes, the company confirmed confirmed that the antibody drug loses potency to the extent we may need replacement therapies if omicron becoming dominant the drug still works against delta, but regeneron's ceo told us the company has already developed new potential medicines. >> we're excited to say this morning that we actually have a whole host of new antibodies, which can work against both omicron and delta. so while the current cocktail doesn't, this sort of emphasizes the need to play the long game here. >> regeneron expects it could start human testing of those drugs early next year. eli lilly also says it has a follow-on medicine works again omicron. meanwhile, europe's drug regulator indicating today countries that i ban to start uses pfizer's pill even before it's officially authorized in the u.s., the fda has yesterday to act on either pfizer or merck's pills. >>> advisers advising against the j&j vaccine? >> yeah, the agency's committee of outside advisers met to discuss th

. >> where would you be putting your money >> regeneron has gone into the next year. that was just a temporary blip they get 50% of the value. we've seen a lot more data over the next year. starting to get a very nice extension that will extend well into 2030. we have the target price today of regeneron even though it is still up from its lows of the year >> clearly, you still see opportunity. great discussion thank you for joining us today appreciate it. >> nice to see you take care. >>> the latest options opportunity with market rebellion. joining us in a couple seconds stay with us >>> welcome back the cdc is back with the latest. looking at the tech sector and asked within tech, what specific area will be the biggest gainer in the next year 30% software, 29% like cloud and 7% investing in hardware joining me now, cnbc contributor. good to see you. happy holidays you saw that, where would you be putting your money >> well, as you know, we get that end of the year tax loss harvesting every year for whatever stock they have that has gone down, they'll try to matchup

regeneron is a biotech name, but it's profitable. that makes this tangible, not co conceptual, because it trades in ear earnings, not sales. so if regeneron tells a great story, the stock will be rewarded if it were losing money, i would say pass i wouldn't even mention it in the game plan, but it's not. it's making money. it's making money hand over fist i said over and over again, we're living through the roaring '20s this is a booming economy and the vast majority of companies are doing well, except the ones that lack the ability to raise prices so one of these challenge companies is a company you know called campbell's soup, and it struggled with end sales growth, but they have an investor day next tuesday we know hormel was able to push up prices and the stock did well campbells isn't part of the club, but maybe they can be. while the stock is cheap, it's not cheap enough along with data showing they can get away with rising prices. i love it if campbells soup could pull it off. i'm not holding my breath. judging from the quarte

right now but regeneron's ceo told us the company has already developed new potential medicines. >> we're excited to say this morning that we actually have a whole host of new antibodies, which can work against both omicron and delta. so while the current cocktail doesn't, this sort of emphasizes the need to play the long game here. >> regeneron expects it could start human testing of those drugs early next year. eli lilly also says it has a follow-on medicine even further along that works against omicron. the question will be how quickly these can get through the fda. meanwhile, europe's drug regulator indicating today countries might want to start using pfizer's anti-viral pill for covid even before it's officially authorized. amid their big surge here in the u.s., the fda has yet to act on either pfizer or merck's pills, shep. >> experts from the cdc today advising against getting the j&j vaccine? >> yeah, the agency's committee of outside advisers met to discuss the numbers on the rare blood clots associated with the j&j shot there have now been nine deaths associated with this condit

what we got out of is we liquidated tjx in the quality growth to buy regeneron and we trimmed comcasty the others in our dividend portfolio. so, you know, i wanted to comment. i'm getting a lot of comments on the helmet in the background and the steeler helmet guys, i don't care if they're 0 and 16 i'm going to be a steelers fan the greatest comeback in history last night. >> don't talk about the steelers don't talk about them. i took the steelers plus three last night and they being not get it done at the end of the game and i had delvin cook on the bench on my fantasy team and last night was terrible for many reasons. pete najarian, you're back come on now, big ben, he's like my age you have academy sports to your equity portfolio who is academy sports and why are you adding them? >> if you're familiar with cabela's it's a great comparison they absolutely crushed it last night. when you look at the numbers that they were able to put up, sully and they've done this quarter after quarter and you take a look at the stock over this year and it's doubled it's absolutely been an extraordi

is that is effective as regeneron and eli lilly -- -- >> eventually valuable for high-risk people.ement with you. when we are not talking about and it seems strange because we should all be rooting for solutions. but people either read for vaccines or -- we should be rooting for vaccines and solutions like the regeneron and the antibody cocktails as well as the pills that we are now discovering. i never understood from the very get go why we weren't all on the same page on this. we want those to exist. and these kinds of messages are frustrating for me because i talk about them and these are examples of how we can unleash the power of innovation. i've been traveling around the state of pennsylvania and i feel so optimistic because people of great ideas. but we find political issues, though mike suffocating these ideas, holding us back on we find people reading for solutiot solutions based on political ideas. that is harmful. >> sean: by the way, i have been watching with some amusement why you would ever leave this great, highly successful show to run for office. that is your choic

we used our best science and recognized that the regeneron and the lilly were not going to work, but there was still plenty of delta. we made sure people use that, but we pulled back for a number of weeks the gsk vir monoclonal. that allowed to us have more we shipped out this last week, we are shipping out more. we have about 300,000 regimens in january. we just bought another 600,000 for the first quarter. we're buying everything we can get our hands on, but the important part, if you put up your graphic again, you see that those monoclonals are only -- they're very important. but the great news is, you know, we have now that medicine cabinet, certainly for our patients, we have oral antivirals too that were approved yesterday and today. we have a new intravenous, the drug is not new, remdesivir has been out there. there was a paper in "the new england journal" yesterday, profound results for use as in and out patient to prevent hospitalization. there is a range of therapies. there is one that is also very important, there is a monoclonal that just got authorized and that's the ast

and regeneron, makers of an antibody treatment that can reduce risk of hospitalization and death by 70% in high-risk patients, says early evidence shows it is less effective against omicron and may need to be updated. meanwhile, the u.s. is stepping up its surveillance system for tracking new coronavirus variants. >> we are now sequencing approximately 80,000 samples per week. about one in every seven pcr-positive cases. that's more than any other country. >> reporter: currently testing antibody response against the new variant is dr. david ho of columbia university. >> we suspect that they will be a significant amount of loss in activity. the antibodies that have been elicited by the current vaccine may have worked very well against the original strain or even the delta strain but will work less well against omicron. >> reporter: what does that mean for the amount of time it could now take to be protected against this strain? >> if the loss in vaccine efficacy were to be substantial, then companies will jump into action to make a new vaccine. that might require anywhere from three mont

regeneron out with data about its antibody treatment and efficacy against the variant meg tirrell has details. >> reporter: morgan, it hasn't been expected base and modeling but now regeneron confirms its antibody cocktail loses potency against the omicron potency. that potency against the delta variant, currently the one circulating in the united states omicron is growing quickly across the united states regeneron saying it has next generation drugs active against both omicron and delta as well as other variants of concern and could start human trials first quarter of next year we talked to the ceo this morning about this finding here's what he said. >> excited to say this morning that we actually have a whole host of new antibodies which can work against both omicron and delta. while the current cocktail doesn't, this sort of emphasizes the need to play the long game here. >> so a big question, of course what is the regulatory pathway of that look like? lilly has a new antibody holding up against omicron and advisers to the cdc is meeting to discuss whether to tailor the recommendat

one, regeneron is a treatment for mild covid. then we have a camera, inpatient treatment for severe covid. then we have remdesivir, given for mild medium conditions and it doesn't actually improve mortality rates, but it shortens inpatient stays and gets better -- people better faster if they have medium covid. we also know that we have two new treatments coming straight out from merck and pfizer. they have been approved by the fda but have not been delivered to the market yet and provided to patients in regular health care settings due to certain delivery production supply chain issues that i believe will be solved very, very soon. between the vaccine and, to your question, i will share it again and really underscore this, the mrna vaccine is a safe vaccine. millions and millions of people around the world, globally, have received the vaccine and are doing great. without the vaccines people would be dying everywhere, every day in the streets. god bless we have those vaccines and they are safe. they have been scientifically prove

regeneron said its monoclonal antibody may not be as effective.h how much clarity we don't have an omicron, we spoke with a top fda official, he told us two to four weeks before we know whether the vaccines we have already taken work. if they don't work well enough, probably looking around april to create a booster that's specifically made for omicron. we're certainly hoping for the former, but by year's end, hopefully we will have some more clarity. >> i hope so. thanks a lot for that jack. coming up, a billionaire investor react for the first time to widespread criticism about his controversial remarks about ♪ [laughing and giggling] (woman) hey dad. miss us? (vo) reflect on the past, celebrate the future. with the season of audi. standing up to the chinese communist party, the head of the women's tennis association is spending all tournaments -- suspending all tournaments in china over its treatment of a tennis player, a tennis star who accused of a former top chinese government official of sexual assault. boston celtics player told maria barti

i got the monoclonal, it was the regeneron we got, we call them mab's, 24 hours later i was perfect.or who gave me those treatments. he's in charge of a hospital in new york state. he says they are totally out, completely out. why the shortages? i don't understand why we didn't do more to stockpile this wonderful drug. >> well, i think first, we need to understand what they're indicated for , and these monoclonal antibodies are indicated for folks who have been exposed at a high risk, or they have tested positive and these are great treatments that work for a limited period of time. they've been shown to reduce your risk of going to the hospital or to be admitted to the hospital or go to the icu by 80% so it's not for hospitalized patients but folks like you who contracted the disease and were able to get treated quickly. as far as why they're in short supply, i think that probably, they may not be used appropriate ly in some cases, they may be overused in other cases and also i think that we did not focus appropriately on producing enough of them. david: well as you well know, the s

regeneron said its monoclonal antibody may not be as effective.h how much clarity we don't have an omicron, we spoke with a top fda official, he told us two to four weeks before we know whether the vaccines we have already taken work. if they don't work well enough, probably looking around april to create a booster that's specifically made for omicron. we're certainly hoping for the former, but by year's end, hopefully we will have some more clarity. >> i hope so. thanks a lot for that jack. coming up, a billionaire investor react for the first time to widespread criticism about his controversial remarks about his controversial remarks about ch trelegy for copd. [coughing] ♪ birds flyin' high, you know how i feel. ♪ ♪ breeze driftin' on by... ♪ if you've been playing down your copd,... ♪ it's a new dawn, it's a new day,... ♪ ...it's time to make a stand. start a new day with trelegy. ♪...and i'm feelin' good. ♪ no once-daily copd medicine... has the power to treat copd in as many ways as trelegy. with three medicines in one inhaler, trelegy helps

regeneron now says its monoclonal antibody treatment may not work as well on omicron as it does on other strains. >> we've started with very potent antibodies we have to look at how much the hit is, but more importantly we have to get ready for the next one. >> reporter: moderna's ceo warned today he expects a material drop in existing vaccines' protection against omicron. while late today, pfizer applied for the first emergency use authorization of covid boosters for 16 and 17-year-olds there's no timeline on when the fda could act. also late today, a federal judge issued a preliminary injunction halting the start of president biden's national vaccine mandate for health care workers which was set to take effect next week, lester. >> gabe, back to merck's pill that an fda advisory panel recommended for approval, what happens now? >> reporter: well, lester, it now will go before the full fda in the coming days. now, the advisory panel's vote was very close, 13 to 10, and many of the panelists said they only wanted the pill used by high-risk patients and not pregnant women, lester >> gabe

regeneron said its monoclonal antibody may not be as effective.h how much clarity we don't have an omicron, we spoke with a top fda official, he told us two to four weeks before we know whether the vaccines we have already taken work. if they don't work well enough, probably looking around april to create a booster that's specifically made for omicron. we're certainly hoping for the former, but by year's end, hopefully we will have some more clarity. >> i hope so. thanks a lot for that jack. coming up, a billionaire investor react for the first time to widespread criticism about his controversial remarks ♪ about his controversial remarks about china. (man) still asleep. (woman vo) so, where to next? (vo) reflect on the past, celebrate the future. with the season of audi. (vo) t-mobile for business helps small business owners prosper during their most important time of year. when you switch to t-mobile and bring your own device, we'll pay off your phone up to $1000. you can keep your phone. keep your number. and get your employees connected on the

regeneron said its monoclonal antibody may not be as effective.h how much clarity we don't have an omicron, we spoke with a top fda official, he told us two to four weeks before we know whether the vaccines we have already taken work. if they don't work well enough, probably looking around april to create a booster that's specifically made for omicron. we're certainly hoping for the former, but by year's end, hopefully we will have some more clarity. >> i hope so. thanks a lot for that jack. coming up, a billionaire investor react for the first time to widespread criticism about his controversial remarks about china. that's next. metastatic breast cancer is relentless, but i'm relentless every day. and having more days is possible with verzenio, proven to help you live significantly longer when taken with fulvestrant. verzenio + fulvestrant is for women with hr+, her2- metastatic breast cancer that has progressed after hormone therapy. diarrhea is common, may be severe, or cause dehydration or infection. at the first sign, call your doctor, start

in china there are two still maintaining the high levels of he have kas si they look better than regeneron and lily that means they have legs and they can make a million courses next year that could go up for a large quantity >> they've got the vablt and manufacturing and treatment. good news. >> a former trump official, officially in contempt of congress a record-breaking night in the nba. back after this. >> announcer: today's big number $9 $9 $9.5 trillion. that's houch total etfs have reached this year. rehadoleheevel the a the end of 2018. at vanguard, you're more than just an investor, you're an owner with access to financial advice, tools and a personalized plan that helps you build a future for those you love. vanguard. become an owner. firefighter maggie gronewald knows how to handle dry weather... ...and dry, cracked skin. new gold bond advanced healing ointment. restore healthy skin, with no sticky feeling. gold bond. champion your skin. >>> welcome back a lot going on outside the world of business. let's find out with the key headlines with pm and more on that >> overnight, the

and regeneron, makers of an antibody treatment that can reduce risk of hospitalization and death by 70%n high-risk patients, says early evidence shows it is less effective against omicron and may need to be updated. meanwhile, the u.s. is stepping up its surveillance system for tracking new coronavirus variants. >> we are now sequencing approximately 80,000 samples per week, about one in every seven p.c.r.-positive cases. and that's more than any other country. >> reporter: currently testing antibody response against the new variant is dr. david ho of columbia university. >> we suspect that there will be a significant amount of loss in activity. the antibodies that had been elicited by the current vaccine may have worked very well against the original strain, or even the delta strain, but will work less well against omicron. >> reporter: what does that mean for the amount of time it could now take to be protected against this strain? >> if the loss in vaccine efficacy were to be substantial, then companies will jump in to action to make new vaccine. that might require anywhere from thre

and regeneron -- makers of an antibody treatment that can reduce risk of hospitalization and death by 70% in high-risk patients -- says early evidence shows it is less effective against omicron and may need to be updated. meanwhile, the u.s. is stepping up its surveillance system for tracking new coronavirus variants. >> we are now sequencing approximately 80,000 samples per week. about one in every seven pcr positive cases and that's more than any other country. >> reporter: currently, testing antibody response against the new variant is dr. david ho of columbia university. >> we suspect that there will be a significant amount of loss in activity. the antibodies that have been elicited by the current vaccine may have worked very well against the original strain or even the delta strain but will work less well against omicron. >> what does that mean for the amount of time it could now take to be protected against this strain? >> if the loss in vaccine efficacy were to be substantial, then companies will jump into action to make new vaccine. that might require anywhere from three month

marc in south carolina >> hi, jim, watching ever since you recommended regeneron at $5 a share. >> myss. >> caller: i know. exciting about this company, amazon are major investors, and one of the most successful biotech firms in history with shares buying hand over fist, flush with cash. 350 million in the bank. naut >> nautilus, that's interesting company. look, this one is too small for me to point and say you're going to love it i got to do work on it does seem strange because looks like they're very involved, let me do work alex in louisiana. >> caller: hey, jim, appreciate the opportunity to speak with you, wishing you speedy recovery. >> thank you, buddy, really appreciate it. what's up? >> caller: my question is corning. had eye on corning for years because gorilla glass is used across manufacturers and product lines from everything, apple to android, apple invested 45 million this year. >> they're unassailable in manufacturing but there are so many better companies, can't recommend the stock. jim in iowa. >> caller: thanks for taking my call, happy holidays >> same to you what

i mean, when i heard that i thought, wow, because the regeneron infusion medicine was among the most right? >> so first of all, when it comes to monoclonal antibodies, regeneron and eli lilly their cocktail may not be as robust against this variant. there is a third monoclonal antibody which targets a different part of the spike protein. they said theirs does work. with the vaccines, it matters what you're trying to you achieve with the vaccine. it might be something that causes more breakthrough infections but those infections will be mild because of the other protection that the vaccine gives you. it's not just aceds and protection -- antibodies and protectionses against mild disease. even if it might allow mild infectionses to slip through, serious illness, hospitalization and death will still likely be protected. there may be a need to update the vaccine to get more protection. what we're hearing from south africa and other countries is the people that are hospitalized tend to be not vaccinated which is what we expect and the cases we're seeing that are breakthroughs are not very

going against something we heard from regeneron. it has been decent news in the last 24 hours. if you want -- tom: if you want to speak about south africa and the fears we face, we will speak to be professor at johns hopkins university. christopher is one of the great international students of these horrific pandemic diseases we see. when you heard about omicron and you dovetail it with the phrase south africa, how did you respond? >> we were very concerned because the area where the omicron virus spread most, where johannesburg and victoria art and the surrounding provinces just got through a very severe wave of delta. they had a delta surge from july until september this past year. you would expect this is a highly immune population. more than 70% of adults had covid during the surge. tom: i take issue with the non-science media that think this is an episode of er. where everything will get wrapped up at the end of the hour. that is not the case. it is about serious, serious science. you mentioned in our early -- opening discussion the mutations of the virus, the study of ant

you remember that both the lily and regeneron were already sort of a composite they were epitopes ofeed to be modified as well or do we need to test to see if they work as well on the variant? and how long does it take to make those are they much more difficult than -- monoclonals must be a little more difficult than vaccines. >> it sounds like from modeling work that's been done that both the regeneron and lily antibody cocktails will need to be updated. we haven't seen the actual lab studies done yet so we will see that regeneron of course has a library of antibodies, already some in the clinic human testing where they could update this and we'll have to see how well those neutralize omicron that manufacturing process takes time because these are grown in chinese hamster owe sster ovar it does take time and there's more steps along the ay. >> who thought the first time to use some chinese hamster ovary let's try some chinese hamster ovary cells. of course henrietta lack, there's a movie made about her, remember >> she's not a chinese hamster but there's a lawsuit over helicells rig

regeneron and eli lilly say tests show their drugs are not as potent against omicron. they're working on new drugs but will take a few months for those to get going. glaxosmithkline has a drug that works well against omicron but is not widely available in the united states as of yet. more "politics nation" right after this break. reak psoriasis really messes with you. try. hope. fail. no one should suffer like that. i started cosentyx®. five years clear. real people with psoriasis look and feel better with cosentyx. don't use if you're allergic to cosentyx. before starting get checked for tuberculosis. an increased risk of infection, some serious and a lowered ability to fight them may occur. tell your doctor about an infection or symptoms or if you had a vaccine or plan to. tell your doctor if your crohn's disease symptoms develop or worsen. serious allergic reaction may occur. best move i've ever made. ask your dermatologist about cosentyx®. ask your dermatologist ♪ ♪ ♪ hey google. ♪ ♪ ♪ ♪ ♪ ♪ music: ♪ “i got you babe” by etta james ♪ get groceries, gifts, & more fas

this one monoclonal antibody is expected to be effective, but there are monoclonal antibodies by regeneron and lil li that are unlikely to be effective. there is another drug that prevents covid-19, prevents it, and that does seem to have neutralizing activity against omicron. unfortunately, losing two potential treatments for people with covid-19, that's obviously not good. those companies have gone back to the lab to try to find a version of their drugs that will work against this new highly transmissible variant. poppy? >> okay. before you go, elizabeth, the cdc made a really important rule change in the last 24 hours that affects health care workers. what is it? >> reporter: it is. so, they shortened the isolation period. perhaps more importantly, they really put the power in the hands of hospitals and medical centers to make decisions about how long people stay out. so we're talking about people who are infected, who do have covid-19, but they have mild symptoms or maybe completely asymptomatic. you don't want to keep those doctors and nurses and other health care workers out for too

we got a vaccine done -- three vaccines done and tremendous therapeutics like regeneron and other thingshave saved a lot of other lives. i think this would have been the spanish flu of 1919 when hundreds of millions died. take credit for it. what we've done is historic. don't let them take it away. you're playing right into their hands when you say, oh, the vaccine. if you don't want to take it, you shouldn't be forced to take it. no mandate. but take credit because we saved tens of millions of lives. take credit. don't let them take that away from you. >> that's an interesting slight shift in rhetoric there. obviously he's opposing mandates, but he seems almost encouraging about the vaccines? that's something to watch. we know in the past when he would talk about vaccines and got booed, he would immediately stop. we'll have to watch. >>> meanwhile, coronavirus cases continue to explode in the united kingdom driven by the omicron variant. now prime minister boris johnson is talking about strict measures. >> we've got cases of omicron surging across the country now, and we've got hospital

we used our best science and recognized that the regeneron and the lilley were not going to work, and we pulled back for a number of weeks the gsk monoclonal, and that allowed us to have more that we shipped out this last week. we are shipping out more -- we have about 300,000 regimens in january. we just bought another 600,000 for the first quarter. you know, we're buying everything we can get our hands on. but the important part, as you put up your graphic again, you see that those monoclonals are only -- they are very important. but the great news is, you know, we have now that medicine for our patients. we have oral antiviral, two that were approved yesterday and today. we have a new intravenous -- the drug is not new. it's been out there, but remdesivir said that the people in the new england journal found profound results to prevent hospitalization. so there's a range of therapy. there is one that is very important. there is a monoclonal that just got authorized, and that's the astrazeneca. and that's for prevention, even before you get infected for people who are immunocompromi

had to take the regeneron monoclonal antibody cocktail that helped save his life presumably and so forad it, although he wasn't acknowledging it and it's unclear to me why he wasn't getting really tested with an accurate pcr test. jim, you were there. you were covering all of that. go ahead. make your point. >> well, i was just going to say, wolf, that maggie and jim will remember. we all suspected that it wasn't likely that he had just tested positive the day before he had to be shipped off to the hospital so sick. i mean, that's not the way covid works. you get -- you know, you get infected and then at least at that time it took several days before you really got that sick. so this really did sort of, you know, underscore what we all knew which was they just weren't taking any of this seriously. he got the test. he walked around kind of, you know, regardless of the impact on other people and i think that's -- we all reported that at the time, this indifference that they had to all the restrictions but this brought it into relief. >> one reason why i think you can put some stock in wh

he talks about the regeneron treatment that trump was on at the time but notes that the white house doctor said to mark meadows that judging by the details he had given meadows, quote, it was clear that the staff at walter reed was prepared for a long stay, weeks, maybe longer, when donald trump first arrived there last october. this is of course a major departure from how the white house publicized trump's health at the time, and we've also learned through the reporting on this book that there are other things that the white house withheld regarding trump's covid-19 diagnosis and the way they handled internal covid-19 outbreaks. cnn has reached out to donald trump's team for comment on this meater, but they have not gotten ou back to us. >>> coming up for us this hour, as temperatures are falling across the united states, so are energy prices. what's driving down those costs and also the price at the gas pump? that's next. to create 400 scholarships this month alone. because we believe everybybody deserves a chance. see what scholarships you may qualify for at phoenix.edu this is your hom

regeneron is not out there. work not available. to take the people not vaccinated. going to be a dark winter it's because the year that's been given to team biden that operation warp speed gifted them vaccine and the supply chain has been squandered on politics over big tax hikes instead of taking on covid. so they are on their heels. juan can disagree with that. that's not messaging. that's just true. >> bret: we will see where build back better and whether they resurrect some of that in the new year. panel, stand by if you would. when we come back, tomorrow's headlines with the panel. ♪ ♪♪ ♪♪ ♪♪ ♪♪ experience the power of sanctuary at the lincoln wish list event. thinkorswim® by td ameritrade is more than a trading platform. it's an entire trading experience. with innovation that lets you customize interfaces, charts and orders to your style of trading. personalized education to expand your perspective. and a dedicated trade desk of expert-level support. that will push you to be even better. and just might change how you trade—fo

they we have relied on antibody drugs to prevent severe disease and hospitalizations but drugmakers regeneron and eli lilly say that recent test show that their therapies right now are not as potent against the omicron strain. the companies have new drugs in the works, but they won't be ready for months. glaxo smith kline does have an antibody treatment that could fight omicron. but it is not widely available right now in the u.s.. today, massachusetts senator elizabeth warren announced that she has tested positive for covid-19 in a tweet today. she says it is a breakthrough case. warren says that she is fully vaccinated and boosted as a member of the senate. she undergoes regular testing warren says that she only has mild symptoms and that she's grateful for the protection that she has for being vaccinated. also new jersey senator cory booker announced that he is also tested positive for covid-19 booker said that he first started feeling symptoms yesterday and that they are relatively mild. in a statement he said that he is fully vaccinated and boosted as well. both senators now urging any a

we've been listening to a number of governors, desantis and others tout regeneron as this magical cure for covid. it's not. vaccines are better. but losing the ability to give these monoclonal antibodies to high risk patients is a huge blow to those of us that are trying to keep high risk patients out of the emergency department and the hospital. i'm hopeful that paxlovid will fill that gap but time will tell. >> we know the administration is hoping to boost supplies of the antibodies as well. dr. megan ranney, always good to have you on. >> thank you. >>> breaking news next, a top trump ally in congress was asked to talk with the january 6th committee. how will congressman jim jordan respond? >>> plus will the omicron surge be short-lived? there are encouraging clues from south africa where it first struck. that's just ahead. gifts you rea, really, really, can't wait to unwrap. ♪ joy. fully. ♪ (burke) this is why you want farmers claim forgiveness... [echoing] claim forgiveness-ness, your home premium won't go up just because of this. (woman) wow, that's something. (burke) you get a w

. >> neil: so regeneron, what they're working on here, it doesn't seem like it's as promising as ther is it still a ways off? >> it's a little ways off. i think the science is not there yet. we continue to work on these various treatments. i think the most important thing we have to do is use the tools in hand and continue to innovate. i think we need to continue to boost and maybe tweak them year after year. >> neil: thanks, dr. dr. kevin campbell following this. some companies that used have hard positions say get back to work as soon as you could post pandemic are now reversing themselves. citigroup is telling new york and new jersey staffers that they can work from home again. they're not setting a deadline on that. others are doing the same after a spike in cases here and whether it warrant as more conservative approach to work. let's go to charlie gasparino. this represent as big 180 for some. what's going on? >> morgan stanley with the biggest brokerage sales force in america. 18,000 brokers. financial advisers that deal with small investors. they're telling the brokers in new

but we should be doing is saying to regeneron is user same technique.udies, but it's not going to take you six months. were going to get your new monoclonal antibodies approved within a month. that's a reasonable thing as long as they are taken voluntarily. you do not mandate people to take the treatment. people discover very quickly that therapeutic success and they will clamor for this treatment. don't get any of that from function. he wants you to do stuff that does not work. cloth mack has no utility and cloth masks do not work. but that studies out there saying instead of let's beat up vaccine approval and speed up monoclonal antibody approval that could save lives. >> john: senator rand paul from the great state of kentucky. thank you for joining us. the white house considering a new crackdown on travel as fears of the omicron variant spreads. >> dr. anthony fauci also said that he could see boosters as part of a mandate. not there yet, but he could see it. also contact tracing for that individual that has omicron variant and those other people th

we saw new guidelines from hhs on the antibody drugs, abu the regeneron and lilly, of which we have more't work guess the omicron. we have a very limited supply that does hold up, but hhss, that should be reserved for the highest-risk people, and you can tell if you use -- if you're in an area with more than 20% prevalence of omicron, which sounds like it will be many places right now overy seen, so its a different situation with the antibody drugs. >> and it's changing faster than we with can provide guidelines to health professionals. >>> let's send it over to mike santoli who joins us at the new york stock exchange this morning, mike. >> good morning. all we've been talking about with this new strain, new wave is just another thing that has the market cornered. at the same time we have this narrative of fiscal and month tar tightening along with this year-end liquidation, and some of the highest concentrated growth stocks. it's all amounted to basically a trip ban dock tout lower end of what would look like a two-month trading range basically haying from last summer is the market is g

he was in his t-shirt with muffled hair and bloodshot eyes, getting regeneron in his veins in his bedeally bad shape. >> yeah. you know, i think it is really important. i mean, i remember atd the tim because he was getting r remd remdesivir, which you don't get that and go home afterwards. you stay in the hospital. the regimen he was getting made all the reporters covering him very skeptical about whether his health was in actually a much worse place. and the reporting -- well, the disclosures of this book seem to validate that. i got covid after that, but i know that if my blood oxygen level had been 86%, i would have been in the hospital a long time before then. it would have been an emergency phone call and an ambulance pickup. so i think there are concerns. the reason why anyone should care about this now is because if there is a 2024 campaign, we see now a pattern that the public story, the public messaging is much different than what's really going on behind the scenes. if that's true about a president's health, it could be true about other things. >> you know, i think that -- >

not me.he we.l we got a vaccine done, three t vaccines done and tremendous therapeutics like regeneron and other things that have saved a i lot of lives. take credit for it. it is great. what we've done is historic. don't let them take it away. don't take it away from ourselves. you're playing right into their hands when you sort of like oh, the vaccine. if you don't want to take it you shouldn't be forced to take it. no mandates.d but take credit because we saved tens of millions of lives. >> both the president and i are vaxed. did you get the booster? >> yes >> i got it, too. okay.u >> oh, don't, don't. no. that's all right. a very tiny group over there. >> you hear the people. they cheer only when he says you shouldn't be forced to take it. then they heckle when he says he got the booster. trump says, well there is a tinf number. this is a guy who got vaccinated in the white house in secret. so this is a change. a in theable one. my personal theory is donald trump is going to run for president again and whatever you iy about the guy he is fairly a canny politically and he understand

on monoclonals, most of them, regeneron, lily, they don't work well against omicron until a week or so ago it was mostly delta and now it's omicron so that's a real problem and we've got to ramp up production so other monoclonals that do and build new ones. that's going to take a little time but yeah, we've got to put all of our efforts, defense production act, everything we need to throw at getting more monoclonals out there for people having bad breakthrough infections. >> you said president biden is not going to convince those who are unvaxed and dug in to now get the vaccine, however, former president trump might be able to. here is what he said yesterday. >> what we've done is historic. don't let them take away, don't take it away from ourselves. you're playing right into their hands when you sort of like oh, the vaccine. if you don't want to take it, you shouldn't be forced to take it. no mandates but take credit because we saved tens of millions of lives. >> both the president and i are vaxed. did you get the booster? >> yes. >> i got it, too. okay, so -- >> don't, don't, don't,

expected to hold up their efficacy against that we have seen it change with the antibody drugs from regeneronnd eli lilly in particular, they lose efficacy against this virulent there's another from glaxosmithkline that holds up, but we spoke with them about how they're trying to fix it here is what he said >> we seem to be the only antibody left with activity against omicron. we are doing everything we can to accelerate the supply we came here to deal with infectious diseases, to save patients, and we're in the middle of a pandemic we are doing everything we can from early morning to late at night to get more supply to the people who need it >> so as they are working on this and we're seeing the companies, pfizer and potentially merck, getting the pills out there we are seeing cases start to rise steeply off an already big wave from delta, now with omicron contributing, approaching 150,000 cases a day. jon, there are reports and even more today that it will be less severe and fewer people overall will be sent to hospitals, but they're worried about the hospitals being overwhelmed by the shee

we're not giving regeneron fast enough to a lot of places.ll that spells trouble in the coming weeks. >> i want to dig into some of what you laid out for us dr. hotez but first, gary standing by for us in new jersey with the highest cases ever in that state, gary. talk me through what you have been seeing so far there. >> reporter: good morning, guys. we're at a covid testing line site here in the mall and we see hundreds of cars coming through here throughout the morning and expecting hundreds more throughout the day. we're talking to some folks out here getting tested. some say just as a precaution, just because they wanted to make sure they were safe, others because they're traveling and they need the negative pcr test to travel and others, the one family who said they all tested positive last week, couldn't find a lot of time to get a pcr appointment until this morning. there's frustration across the board when it comes to testing availability here in new jersey. and across the country. we're seeing that across the country as well. but so

about them right now is that the two most commonly used ones, the one from lily and the one from regeneron, they don't work against the omicron variant. that said there is a third monoclonal anti bodies, that when made by glaxosmithkline, that one is harder to get. but that one does work against omicron. and there is a very interesting story about the administration realizing that early on, as soon as omicron reared its head. the on the initiation has been trying hard to marshal its resources of that one monoclonal antibody that still works. they've had interesting decisions as to what to do with the very limited amount that we have. on top of the monoclonal antibodies, yesterday and today, the fda approved to different drugs that you can take at home. anti viral pills that you can take to prevent serious illness. the one from pfizer that was approved yesterday appears to be more effective and appears to have potentially fewer side effects and safety concerns than the one that was approved from work today. the pfizer one appears to be the preferable option from merck. both in terms of effe

the president's eyes hadn't gone away and his hair was a mess from the hours he had spent getting regeneronomes out to say right before trump walked out of the white house to get on the -- on the helicopter to go to walter reed, he had to drop his briefcase, meadows writes, the weight was too much for him. okay. meadows did not write this thinking trump was going to be ple pleased, dana. >> no, he didn't. but anybody who -- like that -- who comes out of a situation writing a book is engaged with a publisher who wants headlines that sell books. and this is the -- the guy who was incredibly close to and there for all of these moments that almost no one else on the planet was. so of course, he is going to write something like that so that people talk about it. so potentially, he sells books. um, and it -- it always blows my mind, erin, and i think you are alluding to this, that people do these things in general but particularly in trump's orbit. and think that it's going to be okay. and that the former president's not going to get mad and he always does. also, not for nothing. have you ever se

so, doctors maybe could have been using, say, regeneron or another monoclonal antibody. >> right. >> made it sound like omicron was the big one out there but it actually wasn't and maybe those drugs would have been useful. we will never know. that time has passed. poppy. >> wow, shows how significant it is to get it right on these. elizabeth, thanks so much for the reporting. let me bring in now democratic governor ned lamont of connecticut. good evening, governor, thank you for joining us. >> hey, poppy, nice to see you again. >> are you concerned that connecticut could soon be in the same place as texas and running out of the only antibody treatment that's proven to work against this variant? >> yeah, i'm concerned. um, our infection rate has gone up a lot. fortunately, connecticut's one of the most vaccinated states in the country and that meant that we are holding our own in keeping capacity at our hospitals. but i see what's going on in new york city where the hospitalizations gone up a lot. so, we're concerned. obviously, monoclonal antibodies, we're going to need that when peo